3M and Thermo Fisher Scientific Enter Collaboration

The companies have come together to increase process efficiency and scalability in commercial therapeutic manufacturing.

By Joel Davies -

3M Separation and Purification Sciences has entered into a global agreement with Thermo Fisher Scientific to allow biopharmaceutical customers more easily pair the 3M™ Harvest RC Chromatographic Clarifier, a single-stage purification solution, with Thermo Scientific HyPerforma Single-Use Bioreactor Systems. The combination is designed to bring greater efficiency and scalability to the therapeutic manufacturing process.

The two companies state that to meet the growing demand for protein-based therapeutics, manufacturers “need advanced technologies and solutions that support reliable and consistent manufacturing processes”. Together, the companies hope that the collaboration will enable manufacturers to capture high titer, high cell-density cultures to improve harvesting and clarification and optimize manufacturing capacity, quality and efficiency.

Released in June 2021, the 3M Harvest RC is 3M’s newest solution that uses proprietary fibrous chromatography media to deliver a single-stage purification solution for recombinant protein therapeutic manufacturing. It’s the latest innovation in harvest and clarification technology, streamlining a traditionally multi-stage harvest clarification process into a single stage.

The technology supports a wide range of cultures with different cell densities, high-packed cell volumes, and cell culture characteristics, allowing manufacturers to achieve predictable performance, without programming every step.

The next-generation process from 3M, which uses the 3M™ Harvest RC. Image: 3M.

“To have 3M Health Care and Thermo Fisher come together like this is an example of two leaders in science collaborating to drive forward next-generation technology for biologics manufacturing”, said Robert Befidi, president, 3M Separation and Purification Sciences. “The 3M Harvest RC in conjunction with Thermo Fisher’s bioreactor systems brings forth a best-in-class solution to optimize manufacturing capacity to produce therapeutics”.

Thermo Fisher manufactures a wide range of single-use bioreactors that are used globally for cell culture production. The Thermo Scientific HyPerforma Single-Use Bioreactor (S.U.B.) is available in sizes from 50 L to 5,000 L models. The first-of-its-size, the 5,000 L S.U.B. is Thermo Fisher’s largest commercially available unit, enabling biopharmaceutical companies to integrate single-use technologies into large-scale bioprocesses, including perfusion cell culture and cGMP manufacturing at very high cell density.

“Combining our highest-capacity bioreactor in the Thermo Scientific HyPerforma DynaDrive S.U.B. portfolio with the 3M Harvest RC Chromatographic Clarifier provides a best-in-class solution to our global biopharma customers”, said Daniella Cramp, senior vice president and president of bioproduction at Thermo Fisher Scientific. “Integration of these technologies helps ensure efficient development of life-saving therapeutics for patients who need them”.

Additional details and commercial availability of products associated with the collaboration between 3M Separation and Purification Sciences and Thermo Fisher will be made available in the coming months.

You can find more information about the collaboration between 3M and Thermo Fisher Scientific on the companies respective websites.

Stay up to date with the most recent automation, computer vision, machine vision and robotics news on MVPro. Read the best stories every Friday with our newsletter.

Automation Articles of the Month

FRAMOS Makes Next-Generation GMSL3 Accessible for Any Embedded Vision Application

May 19, 2022

FRAMOS, a global supplier of custom vision solutions and imaging components, is leading the market...

Delta Launches MH300 AC Motor Drive in EMEA

byJoel Davies

May 13, 2022

Delta has announced the launch of its new advanced compact AC motor drive MH300 series...

SICK Shuffles Executive Board

byJoel Davies

May 11, 2022

After 23 years at SICK (headquartered in Waldkirch), Executive Board member Dr Martin Krämer will...